Natural history of nonfunctioning pituitary macroadenomas followed without intervention: A retrospective cohort study.


Journal

Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653

Informations de publication

Date de publication:
04 2023
Historique:
revised: 29 12 2022
received: 02 09 2022
accepted: 03 01 2023
pubmed: 6 1 2023
medline: 15 3 2023
entrez: 5 1 2023
Statut: ppublish

Résumé

The treatment strategy for nonfunctioning pituitary adenomas (NFPA) includes surgery, radiotherapy, medical treatment, or follow-up. Prior series of patients with NFPAs followed without intervention include small numbers of patients with macroadenomas. This study investigated the natural history of patients with macroadenomas followed without treatment. Retrospective cohort study included patients>18 years, with a diagnosis of NFPA ≥ 10 mm who were naïve to surgery or medical treatment and followed more than 12 months after diagnosis. Patients with chiasmal threat were excluded. Follow-up terminated if the patient underwent surgery, received cabergoline or was lost to follow-up. Data collected included evaluation of tumour characteristics and size by MRI, symptoms including visual disturbances, and hormonal levels. Tumour growth was defined as maximal diameter increase of ≥2 mm. The cohort included 49 patients (30 males, mean age 68.0 ± 12.0 years). At diagnosis, the average tumour size was 17.8 ± 5.9 mm. Mean follow-up time was 4.9 ± 4.9 years. Increase in tumour size occurred in 16 patients (33%), with an average growth of 5.1 ± 4.4 mm. Reduction in tumour size occurred in 10 patients (20%), with a mean decrease of 3.5 ± 1.3 mm. Twenty-three patients remained with stable tumours. Overall, 33 patients (67%) were observed without any intervention; 3 patients were operated and 13 were treated with cabergoline. None of the parameters including age, gender, baseline tumour size, invasiveness, visual disturbances, or hypopituitarism at diagnosis, predicted tumour growth. Observation of NFPAs without surgery or medical therapy is a reasonable approach in selected patients. In our study, no parameter predicted tumour growth.

Identifiants

pubmed: 36600448
doi: 10.1111/cen.14877
doi:

Substances chimiques

Cabergoline LL60K9J05T

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

559-566

Informations de copyright

© 2023 John Wiley & Sons Ltd.

Références

Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91(12):4769-4775. doi:10.1210/jc.2006-1668
Ferrante E, Ferraroni M, Castrignanò T, et al. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol. 2006;155(6):823-829. doi:10.1530/eje.1.02298
Molitch ME. Pituitary incidentalomas. Best Pract Res Clin Endocrinol Metab. 2009;23(5):667-675. doi:10.1016/j.beem.2009.05.001
Huang W, Molitch ME. Management of nonfunctioning pituitary adenomas (NFAs): observation. Pituitary. 2018;21(2):162-167. doi:10.1007/s11102-017-0856-0
Yavropoulou MP, Tsoli M, Barkas K, Kaltsas G, Grossman A. The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs). Endocr Relat Cancer. 2020;27(10):R375-R390. doi:10.1530/ERC-20-0136
Molitch ME. Nonfunctioning pituitary tumors. Handb Clin Neurol. 2014;124:167-184. doi:10.1016/B978-0-444-59602-4.00012-5
Greenman Y, Stern N. Optimal management of non-functioning pituitary adenomas. Endocrine. 2015;50(1):51-55. doi:10.1007/s12020-015-0685-8
Greenman Y, Cooper O, Yaish I, et al. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol. 2016;175(1):63-72. doi:10.1530/EJE-16-0206
Fernández-Balsells MM, Murad MH, Barwise A, et al. Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2011;96(4):905-912. doi:10.1210/jc.2010-1054
Dekkers OM, Hammer S, de Keizer RJW, et al. The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol. 2007;156(2):217-224.
Lenders N, Ikeuchi S, Russell AW, Ho KK, Prins JB, Inder WJ. Longitudinal evaluation of the natural history of conservatively managed nonfunctioning pituitary adenomas. Clin Endocrinol. 2016;84(2):222-228. doi:10.1111/cen.12879
Karavitaki N, Collison K, Halliday J, et al. What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol. 2007;67(6):938-943. doi:10.1111/j.1365-2265.2007.02990.x
Hallén T, Johannsson G, Dahlén R, et al. Genome-wide DNA methylation differences in nonfunctioning pituitary adenomas with and without postsurgical progression. J Clin Endocrinol Metab. 2022;107(8):2318-2328. doi:10.1210/clinem/dgac266
Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol. 1994;41(3):359-364. doi:10.1111/j.1365-2265.1994.tb02557.x
Turner H, Adams C, Wass J. Pituitary tumours in the elderly: a 20 year experience. Eur J Endocrinol. 1999;140(5):383-389. doi:10.1530/eje.0.1400383
Minniti G, Esposito V, Piccirilli M, Fratticci A, Santoro A, Jaffrain-Rea ML. Diagnosis and management of pituitary tumours in the elderly: a review based on personal experience and evidence of literature. Eur J Endocrinol. 2005;153(6):723-735. doi:10.1530/eje.1.02030
Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery. 1997;40(2):225-237. doi:10.1097/00006123-199702000-00001
Molitch ME. Management of incidentally found nonfunctional pituitary tumors. Neurosurg Clin N Am. 2012;23(4):543-553. doi:10.1016/j.nec.2012.06.003
Donovan LE. The natural history of the pituitary incidentaloma. Arch Intern Med. 1995;155(2):181-183.
Feldkamp J, Santen R, Harms E, Aulich A, Mödder U, Scherbaum WA. Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas - results of a prospective study. Clin Endocrinol. 1999;51(1):109-113. doi:10.1046/j.1365-2265.1999.00748.x
Igarashi T, Saeki N, Yamaura A. Long-term magnetic resonance imaging follow-up of asymptomatic sellar tumors. Their natural history and surgical indications. Neurol Med Chir (Tokyo). 1999;39(8):592-599. doi:10.2176/nmc.39.592
Nishizawa S, Ohta S, Yokoyama T, Uemura K. Therapeutic strategy for incidentally found pituitary tumors (“pituitary incidentalomas”). Neurosurgery. 1998;43(6):1344-1348.
Oyama K, Sanno N, Tahara S, Teramoto A. Management of pituitary incidentalomas: according to a survey of pituitary incidentalomas in Japan. Semin Ultrasound, CT MRI. 2005;26(1):47-50. doi:10.1053/j.sult.2004.10.001
Arita K, Tominaga A, Sugiyama K, et al. Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination. J Neurosurg. 2006;104(6):884-891. doi:10.3171/jns.2006.104.6.884
Day PF, Guitelman M, Artese R, et al. Retrospective multicentric study of pituitary incidentalomas. Pituitary. 2004;7(3):145-148. doi:10.1007/s11102-005-1757-1
Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(4):894-904. doi:10.1210/jc.2010-1048
Ertekin T, Acer N, Turgut AT, Aycan K, Özçelik Ö, Turgut M. Comparison of three methods for the estimation of the pituitary gland volume using magnetic resonance imaging: a stereological study. Pituitary. 2011;14(1):31-38. doi:10.1007/s11102-010-0254-3

Auteurs

Irit Ayalon-Dangur (I)

Division of Endocrinology and Metabolism, Rabin Medical Center, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Eyal Robenshtok (E)

Division of Endocrinology and Metabolism, Rabin Medical Center, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Hadar Duskin-Bitan (H)

Division of Endocrinology and Metabolism, Rabin Medical Center, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Gloria Tsvetov (G)

Division of Endocrinology and Metabolism, Rabin Medical Center, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Alex Gorshtein (A)

Division of Endocrinology and Metabolism, Rabin Medical Center, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Amit Akirov (A)

Division of Endocrinology and Metabolism, Rabin Medical Center, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Ilan Shimon (I)

Division of Endocrinology and Metabolism, Rabin Medical Center, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH